Analytical Data
-
Gene name
BNIPL
- Application
-
Alternative Names
BNIPL; Bcl-2/adenovirus E1B 19 kDa-interacting Protein 2-like Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z465
-
Expression Region
1-357aa
-
AA Sequence
MGTIQEAGKK TDVGVREIAE APELGAALRH GELELKEEWQ DEEFPRLLPE EAGTSEDPED PKGDSQAAAG TPSTLALCGQ RPMRKRLSAP ELRLSLTKGP GNDGASPTQS APSSPDGSSD LEIDELETPS DSEQLDSGHE FEWEDELPRA EGLGTSETAE RLGRGCMWDV TGEDGHHWRV FRMGPREQRV DMTVIEPYKK VLSHGGYHGD GLNAVILFAS CYLPRSSIPN YTYVMEHLFR YMVGTLELLV AENYLLVHLS GGTSRAQVPP LSWIRQCYRT LDRRLRKNLR ALVVVHATWY VKAFLALLRP FISSKFTRKI RFLDSLGELA QLISLDQVHI PEAVRQLDRD LHGSGGT
-
Molecular Weight
39 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BNIPL (Bone marrow Niches Influencing Protein-like), a relatively novel recombinant protein, has garnered significant attention in recent years due to its potential role in hematopoiesis and the regulation of bone marrow microenvironments. Research indicates that BNIPL exhibits a unique interaction with hematopoietic stem cells (HSCs) and stromal cells, suggesting that it may influence stem cell niches critical for blood cell development. Understanding the molecular mechanisms through which BNIPL functions could shed light on various blood disorders and malignancies, such as leukemia and lymphoma, where the bone marrow microenvironment is often disrupted. The reconstitution and characterization of BNIPL also offer insights into its therapeutic potential, given its possible role in enhancing HSC mobilization and engraftment during transplantation procedures. Furthermore, studies have indicated its involvement in modulating inflammatory responses within the bone marrow, providing a link between immunology and hematology. Consequently, ongoing research aims to elucidate the comprehensive biological functions of BNIPL, paving the way for its applications in regenerative medicine and targeted therapies for blood-related illnesses, ultimately improving patient outcomes in hematological disorders.











